These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 33246201)

  • 1. A systematic review and meta-analysis of hormone receptor expression in low-grade serous ovarian carcinoma.
    Voutsadakis IA
    Eur J Obstet Gynecol Reprod Biol; 2021 Jan; 256():172-178. PubMed ID: 33246201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network.
    Sehouli J; Braicu EI; Richter R; Denkert C; Jank P; Jurmeister PS; Kunze CA; Budczies J; Darb-Esfahani S; Schmitt WD; Traut A; Grabowski J; Taube ET; Plett H
    Hum Pathol; 2019 Mar; 85():299-308. PubMed ID: 30428389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-grade serous ovarian carcinoma: A comprehensive literature review.
    Goulding EA; Simcock B; McLachlan J; van der Griend R; Sykes P
    Aust N Z J Obstet Gynaecol; 2020 Feb; 60(1):27-33. PubMed ID: 31849044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolving population-based statistics for rare epithelial ovarian cancers.
    Matsuo K; Machida H; Matsuzaki S; Grubbs BH; Klar M; Roman LD; Sood AK; Gershenson DM; Wright JD
    Gynecol Oncol; 2020 Apr; 157(1):3-11. PubMed ID: 31954534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormone maintenance therapy for women with low-grade serous ovarian cancer in the front-line setting: A systematic review.
    Lazurko C; Clark M; Pulman K; Lennox G; May T; Fazelzad R; Gien LT; Zigras T
    Gynecol Oncol; 2021 Oct; 163(1):209-214. PubMed ID: 34325937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cytopathological characterization of ascites for the diagnosis of serous ovarian carcinoma].
    Chang YH; Zou BQ; Cai Y; Yang SD; Zhang Y; Liang JB; Li C
    Zhonghua Zhong Liu Za Zhi; 2023 May; 45(5):424-432. PubMed ID: 37188628
    [No Abstract]   [Full Text] [Related]  

  • 7. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
    Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
    Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone receptor expression profile of low-grade serous ovarian cancers.
    Buttarelli M; Mascilini F; Zannoni GF; Ciucci A; Martinelli E; Filippetti F; Scambia G; Ferrandina G; Gallo D
    Gynecol Oncol; 2017 May; 145(2):352-360. PubMed ID: 28228232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma.
    Murumägi A; Ungureanu D; Khan S; Arjama M; Välimäki K; Ianevski A; Ianevski P; Bergström R; Dini A; Kanerva A; Koivisto-Korander R; Tapper J; Lassus H; Loukovaara M; Mägi A; Hirasawa A; Aoki D; Pietiäinen V; Pellinen T; Bützow R; Aittokallio T; Kallioniemi O
    Br J Cancer; 2023 Feb; 128(4):678-690. PubMed ID: 36476658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormone Receptor Expression in Primary and Recurrent High-Grade Serous Ovarian Cancer and Its Implications in Early Maintenance Treatment.
    Vetter M; Stadlmann S; Bischof E; Georgescu Margarint EL; Schötzau A; Singer G; Heinzelmann-Schwarz V; Montavon C
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promising Therapeutic Impact of a Selective Estrogen Receptor Downregulator, Fulvestrant, as Demonstrated In Vitro upon Low-Grade Serous Ovarian Carcinoma Cell Lines.
    Shanta K; Nakayama K; Hossain MM; Razia S; Ishibashi T; Ishikawa M; Yamashita H; Kanno K; Sato S; Nakayama S; Otsuki Y; Kyo S
    Curr Oncol; 2022 Jun; 29(6):4020-4033. PubMed ID: 35735430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study.
    Matsuo K; Machida H; Grubbs BH; Matsuzaki S; Klar M; Roman LD; Sood AK; Gershenson DM
    Gynecol Oncol; 2020 Apr; 157(1):21-28. PubMed ID: 31954535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1, Ki67, and β-Catenin Immunoexpression Is Not Related to Differentiation, Platinum Response, or Prognosis in Women With Low- and High-Grade Serous Ovarian Carcinoma.
    Sallum LF; Andrade L; Bastos Eloy da Costa L; Ramalho S; Ferracini AC; Natal RA; Brito ABC; Sarian LO; Derchain S
    Int J Gynecol Cancer; 2018 Mar; 28(3):437-447. PubMed ID: 29465506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low grade serous ovarian cancer - A rare disease with increasing therapeutic options.
    Zwimpfer TA; Tal O; Geissler F; Coelho R; Rimmer N; Jacob F; Heinzelmann-Schwarz V
    Cancer Treat Rev; 2023 Jan; 112():102497. PubMed ID: 36525716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in precision therapy of low-grade serous ovarian cancer: A review.
    Wang Q; Cao SH; Li YY; Zhang JB; Yang XH; Zhang B
    Medicine (Baltimore); 2024 Apr; 103(17):e34306. PubMed ID: 38669365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Uncertain Benefit of Adjuvant Chemotherapy in Advanced Low-Grade Serous Ovarian Cancer and the Pivotal Role of Surgical Cytoreduction.
    Johnson RL; Laios A; Jackson D; Nugent D; Orsi NM; Theophilou G; Thangavelu A; de Jong D
    J Clin Med; 2021 Dec; 10(24):. PubMed ID: 34945222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic Review.
    Lazurko C; Linder R; Pulman K; Lennox G; Feigenberg T; Fazelzad R; May T; Zigras T
    Curr Oncol; 2023 Sep; 30(9):8159-8171. PubMed ID: 37754507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors.
    Wong KK; Bateman NW; Ng CW; Tsang YTM; Sun CS; Celestino J; Nguyen TV; Malpica A; Hillman RT; Zhang J; Futreal PA; Rojas C; Conrads KA; Hood BL; Dalgard CL; Wilkerson MD; Phippen NT; Conrads TP; Maxwell GL; Sood AK; Gershenson DM
    J Transl Med; 2022 Dec; 20(1):606. PubMed ID: 36528667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterizing the genomic landscape through the lens of FOLR1 status in low and high grade serous ovarian carcinoma.
    Rushton T; Krause HB; Samec T; Elliott A; Karnezis AN; Toboni MD; Thaker PH; Braxton DR; Oberley M; Gershenson DM; Armstrong DK
    Gynecol Oncol; 2024 Dec; 191():80-85. PubMed ID: 39366033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients.
    Heinzelmann-Schwarz V; Knipprath Mészaros A; Stadlmann S; Jacob F; Schoetzau A; Russell K; Friedlander M; Singer G; Vetter M
    Gynecol Oncol; 2018 Jan; 148(1):79-85. PubMed ID: 29157627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.